Cibisatamab 

Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research^[1].

IgG1-kappa/lambda with domain crossover, trivalent

Human IgG1 (L234A/L235A) kappa, Isotype Control

Human

CD3E & CEACAM5

Cibisatamab (20 nM; co-cultured with CD8 T cells for 7-10 days) is highly sensitive to patient-derived colorectal cancer organoids (PDOs) with high CEA expression, shows resistance to PDOs with low CEA expression, and has low sensitivity to PDOs with mixed CEA expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 73250  [NCBI]

P07766 & Q3UKK2

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

171 kDa

1855925-27-7

Liquid

Colorless to light yellow

[Cibisatamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa/lambda with domain crossover, trivalent

• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Cibisatamab (HY-P99011, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Reyes Gonzalez-Exposito, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019 Apr 15;7(1):101.  [Content Brief]